NIH Researchers Develop Novel Opioid DFNZ with Potent Pain Relief and Reduced Addiction Risk
Key Insights
NIH researchers have identified DFNZ (search), a novel synthetic opioid from the nitazene class that provides potent pain relief without causing respiratory depression or tolerance in preclinical studies.
The drug demonstrated unique pharmacological properties, producing sustained analgesia for at least two hours while only briefly entering the brain and showing minimal withdrawal symptoms in laboratory animals.
Unlike traditional opioids, DFNZ (search) increased brain oxygen levels rather than depressing respiration and did not trigger the rapid dopamine bursts associated with addiction formation.
National Institutes of Health researchers have discovered a breakthrough opioid compound that delivers powerful pain relief while avoiding the respiratory depression, tolerance, and addiction potential that plague current opioid medications. The novel drug, called N-desethyl-fluornitrazene (search) (DFNZ (search)), represents a significant advance in the search for safer pain management alternatives amid the ongoing opioid crisis.
Published in Nature, the study demonstrates that DFNZ (search) provides sustained analgesia without the dangerous side effects typically associated with potent opioids. "Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose," said Dr. Nora D. Volkow, director of NIH's National Institute on Drug Abuse (NIDA (search)). "Developing a highly effective pain medication without these drawbacks would have enormous public health benefits."
Reviving a Shelved Drug Class
The research team investigated nitazenes (search), a class of synthetic opioid compounds that had been abandoned in the 1950s due to their excessive potency. These compounds selectively engage mu-opioid receptors (search), the primary targets for opioid drugs in the brain and peripheral nervous system. However, their extreme potency had made them too dangerous for therapeutic development.
"Our goal was to study the profile, or pharmacology, of these drugs," said Michael Michaelides, Ph.D., senior author and NIDA (search) investigator. "We wanted to decrease the potency and create a potential therapeutic. What we discovered exceeded our expectations."
The team initially focused on a chemical formulation called FNZ (search), which could be administered to rats and tracked using positron emission tomography (PET) imaging. They discovered that FNZ entered the brain only briefly, for approximately five to 10 minutes, yet pain relief persisted for at least two hours. This led them to investigate whether an FNZ metabolite might be responsible for the prolonged effect, ultimately revealing DFNZ (search).
Unprecedented Safety Profile
DFNZ (search) demonstrated remarkable safety characteristics that distinguish it from conventional opioids. At preclinical therapeutic doses, the compound produced a moderate and sustained increase in brain oxygen rather than depressing respiration. Repeated doses did not result in tolerance, drug dependency, or meaningful withdrawal effects.
Among 14 classic opioid withdrawal symptoms, researchers observed only irritability, measured by vocalization when handling DFNZ (search)-treated rats. This minimal withdrawal profile contrasts sharply with traditional opioids, which typically cause severe withdrawal symptoms including respiratory depression, constipation, and physical dependence.
Reduced Addiction Potential
To assess the drug's rewarding effects, researchers trained rats to press a lever for doses of the pain-relieving compound. While animals did self-administer DFNZ (search), indicating some rewarding effect, they immediately stopped drug-seeking behavior when the compound was replaced with saline. This response differs markedly from other opioids such as heroin, morphine, and fentanyl, where animals typically persist in seeking the drug even after it is removed.
The neurochemical explanation for this reduced addiction potential lies in DFNZ (search)'s unique dopamine release pattern. While the compound increases slow-acting dopamine release in the brain's reward circuitry, it does not trigger the rapid dopamine bursts associated with the formation of strong drug-cue associations that drive craving and relapse in addiction.
Clinical Implications and Future Development
"DFNZ (search) has an unprecedented pharmacology for an opioid," Michaelides explained. "It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety. Its capacity to be administered at therapeutic doses without producing respiratory depression is very important."
The findings challenge the prevailing view that high-efficacy mu-opioid receptor drugs are unsuitable for development as safe analgesics. The research team suggests DFNZ (search) should be explored not only as a pain medication but also as a treatment for opioid use disorder (search), potentially offering advantages over current opioid agonist medications that carry respiratory depression risks.
The research team plans to pursue additional preclinical studies to support regulatory approval for human trials. They believe several patient populations may benefit from DFNZ (search), including those in surgical settings and patients with cancer-related or chronic pain (search) who have particularly high needs for effective pain treatment.
This breakthrough comes at a critical time, as more than 125 million Americans live with acute or chronic pain (search), while approximately 80,000 people died from opioid overdoses in 2023. The development of DFNZ (search) represents a potential solution to the dual epidemics of chronic pain and opioid addiction (search) that continue to challenge healthcare systems nationwide.